The FACE-Q Eye Module provided clinical utility in assessing adverse outcomes in a cohort of patients undergoing facial aesthetic procedures.
The researchers aimed to more clearly describe the utility of FACE-Q in terms of psychometric evaluation and adverse effects. The adverse effects included dissatisfaction with scars, dry eyes and eye irritation, according to the results.
The study included 233 patients treated in the U.S. and Canada.
Analysis of the Rasch Measurement Theory indicated that each of the four scales of FACE-Q demonstrated ordered thresholds and good item fit. Other findings showed that Person Separation Index and Cronbach-alpha were 0.83 or greater.
A correlation was reported between higher scores on the eye scales and lower adverse event rates (range, −0.26 to −0.36). Findings from a pre-treatment cohort indicated a correlation between older age and lower scores (range, −0.42 to −0.51) on scales dealing with appearance of the eyes, upper eyelids and lower eyelids.
Patients in the post-treatment group reported significantly better scores than those in the pre-treatment group regarding overall eye appearance along with upper eyelid and lower eyelid appearance. – by Rob Volansky
Disclosure: Three of the researchers report being co-developers of the FACE-Q. One reports being co-founder of Modus Outcomes. Three others report being consultants and investigators for Allergan, Merz, Kythera and Alphaeon.